0
Lyell Immunopharma, Inc. Banner Image

Lyell Immunopharma, Inc.

  • Ticker LYEL
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Lyell Immunopharma, Inc. Logo Image
  • 201-500 Employees
  • Based in South San Francisco, California
Lyell is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. The technologies powering its product candidates are designed to address barriers that limit consistent and long-lasting responses to cell therapy for solid tumors: T-cell exhaustion and lack of durable stemness, which includes the ability to persist andMore self-renew to drive durable tumor cytotoxicity. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technologies to address these barriers in order to develop new medicines with improved durable clinical outcomes. Lyell is based in South San Francisco, California with facilities in Seattle and Bothell, Washington.
Lyell Immunopharma, Inc.

Most Recent Responsibility Report

Lyell Immunopharma, Inc.
MOST RECENT 2022 ESG Report

Lyell Immunopharma, Inc. does not currently have any hardcopy reports on ResponsibilityReports.com. Click the button below to request a report when hardcopies become available.

Request Information
Our service enables potential investors to review the most recent and archived Lyell Immunopharma, Inc. Sustainability Report, Lyell Immunopharma, Inc. Corporate Social Responsibility Report, Lyell Immunopharma, Inc. CSR Report, Lyell Immunopharma, Inc. Corporate Responsibility, Lyell Immunopharma, Inc. CR Report, Lyell Immunopharma, Inc. Citizenship Report, Lyell Immunopharma, Inc. ESG Report, and Lyell Immunopharma, Inc. Environmental Report online.
Lyell Immunopharma, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!